Could a viagra drug help fight liver cancer? new trial tests unlikely combo
NCT ID NCT03785210
First seen Feb 28, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This phase 2 trial tested a combination of three drugs—nivolumab (an immunotherapy), tadalafil (commonly used for erectile dysfunction), and vancomycin (an antibiotic)—in adults with liver cancer or liver metastases from colorectal or pancreatic cancers that had not responded to standard treatments. The goal was to see if the combination could shrink tumors. The study was terminated early after enrolling 22 participants, so the full results are not available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo), tadalafil (Cialis), and oral vancomycin (Vancocin)
What this could lead to
If it works, this combination could shrink liver tumors in patients who have not responded to standard treatments.
What could go wrong
This early-phase trial was terminated early with only 22 participants, so results are limited. The combination may cause serious side effects and may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.